Is there a role for immunotherapy in malignant pleural mesothelioma?

被引：0
|
作者：
Alfredo Tartarone
Rosa Lerose
Michele Aieta
机构：
[1] IRCCS-CROB Referral Cancer Center of Basilicata,Department of Onco
[2] IRCCS-CROB Referral Cancer Center of Basilicata,Hematology, Unit of Medical Oncology
来源：
Medical Oncology | 2018年 / 35卷
关键词：
Malignant pleural mesothelioma; Immunotherapy; Immune checkpoint inhibitors; CAR T cell therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Malignant pleural mesothelioma (MPM) is a very aggressive malignancy, mainly caused by asbestos exposure. Patients with MPM have a poor prognosis that remained substantially unchanged in the last few years and limited effective therapeutic options with no recognized second or further-line therapy. In this context, also in view of the positive results observed in other tumor types, immunotherapy could play a relevant role. This review focuses on the most promising immunotherapies being investigated in MPM.
引用
下载
收藏
相关论文
共 50 条
  • [1] Is there a role for immunotherapy in malignant pleural mesothelioma?
    Tartarone, Alfredo
    Lerose, Rosa
    Aieta, Michele
    MEDICAL ONCOLOGY, 2018, 35 (07)
  • [2] The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
    Banerji, Shantanu
    Meyers, Daniel E.
    Harlos, Craig
    Dawe, David E.
    CURRENT ONCOLOGY, 2021, 28 (06) : 4542 - 4551
  • [3] Immunotherapy in Malignant Pleural Mesothelioma
    de Gooijer, Cornedine J.
    Borm, Frank J.
    Scherpereel, Arnaud
    Baas, Paul
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [4] Immunotherapy in malignant pleural mesothelioma
    Farooqi, Saima Jamil
    Helland, Aslaug
    Haakensen, Vilde Drageset
    Bjaanaes, Maria Moksnes
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2021, 141 (12) : 1167 - 1169
  • [5] Immunotherapy approaches for malignant pleural mesothelioma
    Fennell, Dean A.
    Dulloo, Sean
    Harber, James
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (09) : 573 - 584
  • [6] Immunotherapy approaches for malignant pleural mesothelioma
    Dean A. Fennell
    Sean Dulloo
    James Harber
    Nature Reviews Clinical Oncology, 2022, 19 : 573 - 584
  • [7] Advances in Immunotherapy of Malignant Pleural Mesothelioma
    Liao, Dongying
    Yu, Yongchao
    Mei, Qingyun
    Wang, Ziwei
    Li, Xiaojiang
    Jia, Yingjie
    Kong, Fanming
    ONCOTARGETS AND THERAPY, 2021, 14 : 4477 - 4484
  • [8] Immunotherapy and radiation therapy for malignant pleural mesothelioma
    Alley, Evan W.
    Katz, Sharyn I.
    Cengel, Keith A.
    Simone, Charles B., II
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 (02) : 212 - 219
  • [9] Focus on malignant pleural mesothelioma immunology and immunotherapy
    Porta, Chiara
    Jean, Didier
    Blanquart, Christophe
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [10] Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
    Metaxas, Yannis
    Rivalland, Gareth
    Mauti, Laetitia A.
    Klingbiel, Dirk
    Kao, Steven
    Schmid, Sabine
    Nowak, Anna K.
    Gautschi, Oliver
    Bartnick, Tammo
    Hughes, Brett G.
    Bouchaab, Hasna
    Rothschild, Sacha I.
    Pavlakis, Nick
    Wolleb, Sibylle
    Petrausch, Ulf
    O'Byrne, Kenneth
    Froesch, Patrizia
    Loffler-Baumann, Melanie
    Pratsch-Peter, Susanne
    Russell, Prudence
    Mingrone, Walter
    Savic, Spasenija
    Thapa, Bibhusal
    Fruh, Martin
    Pless, Miklos
    von Moos, Roger
    John, Thomas
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (11) : 1784 - 1791
12345